Melanotan I
A linear analog of α-melanocyte-stimulating hormone (α-MSH) that activates the melanocortin-1 receptor to stimulate eumelanin production. As the drug afamelanotide (SCENESSE), it is FDA-approved for a rare light-sensitivity disorder; the grey-market 'tanning peptide' sold under this name is unapproved.
In plain English
Melanotan I—known in medicine as afamelanotide—is a lab-made copy of a natural hormone fragment that tells skin cells to make more of the dark, UV-absorbing pigment eumelanin. Unlike most peptides discussed on this site, it has been through large, rigorous human trials and is an FDA-approved prescription drug (brand name SCENESSE) for a rare inherited condition called erythropoietic protoporphyria (EPP), in which sunlight causes severe pain. In that narrow, supervised use the evidence is genuinely strong. It is a different molecule from Melanotan II. The unregulated 'Melanotan 1' powder marketed online for cosmetic tanning is not the approved product, is not quality-controlled, and carries real safety and legal concerns.
What it is
Melanotan I is [Nle4-D-Phe7]-α-MSH, a synthetic 13-amino-acid (tridecapeptide) analog of the natural hormone alpha-melanocyte-stimulating hormone (α-MSH). Two substitutions to the native α-MSH sequence make it far more stable and longer-acting. In its pharmaceutical form it is called afamelanotide and is delivered as a slow-release subcutaneous bioabsorbable implant (16 mg) under the brand name SCENESSE, manufactured by Clinuvel. It should not be confused with Melanotan II (a cyclic analog with broader melanocortin-receptor activity and different effects).
Mechanism (summary)
Melanotan I / afamelanotide is an agonist at the melanocortin-1 receptor (MC1R) on melanocytes. Binding activates adenylyl cyclase and raises cyclic AMP, which drives synthesis of eumelanin—the brown-black, UV- and visible-light-absorbing form of melanin—and its transfer to surrounding keratinocytes. Because eumelanin absorbs across a broad range of wavelengths, the resulting pigmentation acts as a light shield that is largely independent of actual sun exposure. In EPP this added photoprotection is thought to reduce the phototoxic reactions caused by accumulated protoporphyrin IX.
Why people research it
- Reducing painful phototoxic (light-triggered) reactions in erythropoietic protoporphyria (EPP), its FDA- and EMA-approved use
- Increasing pain-free tolerance of sunlight and outdoor time, and the associated quality-of-life gains, in EPP patients
- Exploratory interest in other photosensitivity and pigmentary conditions (e.g. polymorphic light eruption, vitiligo) where evidence is still preliminary
- Skin pigmentation/UV photoprotection biology more broadly, which underlies the (unapproved, off-label) cosmetic-tanning interest
Human evidence
For its one approved indication, erythropoietic protoporphyria, the human evidence is unusually strong for a melanocortin peptide. Two phase 3, multicenter, randomized, double-blind, placebo-controlled trials (EU and US, 168 patients total; Langendonk et al., NEJM 2015) showed afamelanotide significantly increased pain-free sunlight exposure and improved quality of life with an acceptable safety profile. These RCTs are reinforced by large real-world observational cohorts (e.g. 115 patients, Br J Dermatol 2015; JAMA Dermatology 2020; a 3-year Swiss cohort, Orphanet J Rare Dis 2020) all reporting longer light tolerance and better quality of life. This evidence base is specific to EPP under medical supervision. There is essentially no rigorous controlled human evidence supporting the unregulated cosmetic-tanning use, and that grey-market product is not the quality-controlled approved drug.
Animal / lab evidence
Preclinical and mechanistic work established that MC1R agonism by α-MSH analogs stimulates eumelanin synthesis and provides UV photoprotection, providing the rationale that was later confirmed in human trials. Because afamelanotide advanced through full human RCTs to regulatory approval, animal data play a comparatively minor role in its current evidence base relative to peptides still confined to the lab.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
The pivotal trials: in two well-controlled studies totaling 168 EPP patients, the afamelanotide implant let people spend significantly more time in the sun without pain and improved their quality of life, with side effects that were generally manageable. This is the evidence that led to drug approval.
A large real-world look at 115 EPP patients found that quality of life roughly doubled after starting the implant and stayed high over years, with only minor side effects. Because there was no control group, it supports—rather than proves—benefit.
This EMA-mandated 'does it work in the real clinic?' study found that EPP patients on afamelanotide spent more time outdoors and felt better, with less painful sun reactions. As an uncontrolled study it adds confirmation rather than definitive proof.
Over three years in a Swiss group of EPP patients, the time they could stay in direct sun before burning jumped from about 10 minutes to about 3 hours, pain dropped, and almost everyone kept up with treatment. It is real-world evidence, not a controlled trial.
A 2024 review that ties the science together: it explains how the drug builds protective pigment and notes the evidence is strong for EPP but still early and unproven for other skin conditions.
History
Melanotan ('melanotan-1') originated from melanocortin research at the University of Arizona in the 1980s aimed at developing a 'sunless tanning' agent that could induce protective pigmentation. The molecule was later developed pharmaceutically as afamelanotide by Clinuvel Pharmaceuticals as a slow-release implant, earning EMA approval in 2014 and FDA approval (SCENESSE) in 2019 for EPP. In parallel, an unregulated grey market emerged selling 'Melanotan 1' (and the related Melanotan II) as injectable tanning peptides, outside any regulatory oversight.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A cyclic melanocortin receptor agonist that increases skin pigmentation; precursor research peptide that led to bremelanotide.
A melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.